SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2641

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.14 (-0.18%)

USD 238.86B
AMGN Amgen Inc

-2.25 (-0.71%)

USD 168.83B
SNY Sanofi ADR

-0.15 (-0.31%)

USD 125.21B
GILD Gilead Sciences Inc

-0.14 (-0.21%)

USD 82.18B
BIIB Biogen Inc

+0.53 (+0.23%)

USD 33.03B
GRFS Grifols SA ADR

+0.03 (+0.39%)

USD 6.07B
AMRN Amarin Corporation PLC

-0.04 (-4.65%)

USD 0.37B
SCLX Scilex Holding Company

+0.03 (+3.45%)

USD 0.10B
MIRA MIRA Pharmaceuticals Inc. Comm..

-0.02 (-3.61%)

USD 0.02B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.64% 40% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.64% 40% F 20% F
Trailing 12 Months  
Capital Gain -83.28% 22% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.28% 22% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.80% 44% F 28% F
Dividend Return -8.80% 44% F 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.59% 22% F 38% F
Risk Adjusted Return -19.74% 44% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.